Drug Trial Radar · NCT00273338
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
Last checked: Nov 20, 2026Latest source record: Nov 6, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,200
Planned (sponsor's estimate)
Start
Jan 2006
Primary completion
Not stated
Study completion Nov 2007
Sponsor
- Lead sponsor
- NovaceaIndustry
- Sponsor type
- Industry
- First posted
- Jan 9, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is: * To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: * To determine the effect of the ASCENT regimen on the rate of thromboembolic events (blood clots) * To determine the effect of the ASCENT regimen on prevention of skeletal-related events (fractures) * A Separate sub-study will be conducted at selected study sites in North America to determine the population PK of DN-101.
Conditions
- Prostate Cancer
Interventions
calcitriolDrug
docetaxelDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
222 sites in 9 countries. Site status is shown where the registry gives one.
Birmingham Hematology & Oncology Associates, LLC
Birmingham, Alabama
Northwest Alabama Cancer Center
Muscle Shoals, Alabama
Alaska Clinical Research Center
Anchorage, Alaska
Hematology Associates - AOA
Phoenix, Arizona
Premiere Oncology of Arizona
Scottsdale, Arizona
Northern Arizona Hematology & Oncology Associates, AOA
Sedona, Arizona
Southern Arizona VA Healthcare System
Tucson, Arizona
U of Arizona / Arizona Cancer Center
Tucson, Arizona
Genesis Cancer Center
Hot Springs, Arkansas
Tower Cancer Research Foundation
Beverly Hills, California
Pacific Shores Medical Group
Long Beach, California
The Angeles Clinic and Research Institute, Inc.
Los Angeles, California
UCLA department of Urology
Los Angeles, California
Veterans Affairs Northern California Health Care System
Martinez, California
Sutter Gould Medical Foundation
Modesto, California
Monterey Bay Oncology
Monterey, California
Comprehensive Cancer Center at
Palm Springs, California
Sutter Cancer Center
Sacramento, California
UCD Cancer Center-Clinical Trials
Sacramento, California
Sharp Memorial Hospital
San Diego, California
California Pacific Medical Center
San Francisco, California
Stanford University
Stanford, California
Rocky Mountain Cancer Centers
Colorado Springs, Colorado
Georgetown University Lombardi Cancer Center
Washington D.C., District of Columbia
Pasco Hernando Oncology Associates, P.A.
14529 Cortez Blvd., Florida
North Broward Medical Center
Deerfield Beach, Florida
Broward Oncology Associates
Fort Lauderdale, Florida
Michael and Dianne Bienes Comprehensive Cancer Center
Fort Lauderdale, Florida
Florida Cancer Specialists
Fort Myers, Florida
Gainesville Hematology Oncology Associates
Gainesville, Florida
University of Florida Shands Cancer Center
Gainesville, Florida
Integrated Community Oncology Network
Jacksonville, Florida
Sylvester Comprehensive Cancer Center, U of Miami
Miami, Florida
Pasco Hernando Oncology Associates P.A.
New Port Richey, Florida
Florida Cancer Institute
New Port Richey, Florida
Innovative Medical Research of South Florida Inc.
North Miami Beach, Florida
Ocala Oncology Center
Ocala, Florida
Cancer Centers of Florida, P.A.
Ocoee, Florida
AYS Urology
Trinity, Florida
Phoebe Cancer Center
Albany, Georgia
Showing 40 of 222 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.